Skip to main content

Peer Review reports

From: Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Original Submission
1 Jun 2023 Submitted Original manuscript
25 Jun 2023 Reviewed Reviewer Report
2 Jul 2023 Reviewed Reviewer Report
11 Jul 2023 Reviewed Reviewer Report - Vipul Sheth
12 Jul 2023 Reviewed Reviewer Report
14 Sep 2023 Author responded Author comments - Haixia Fu
Resubmission - Version 2
14 Sep 2023 Submitted Manuscript version 2
16 Sep 2023 Reviewed Reviewer Report
18 Sep 2023 Reviewed Reviewer Report - Vipul Sheth
29 Sep 2023 Reviewed Reviewer Report
3 Nov 2023 Author responded Author comments - Haixia Fu
Resubmission - Version 3
3 Nov 2023 Submitted Manuscript version 3
20 Nov 2023 Reviewed Reviewer Report
22 Jan 2024 Author responded Author comments - Haixia Fu
Resubmission - Version 4
22 Jan 2024 Submitted Manuscript version 4
Publishing
25 Jan 2024 Editorially accepted
27 Feb 2024 Article published 10.1186/s12916-024-03275-5

You can find further information about peer review here.

Back to article page